z-logo
open-access-imgOpen Access
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil
Author(s) -
Maryam Nemati Shafaee,
Leonardo Roberto da Silva,
Susana Ramalho,
Maíra Teixeira Dória,
Rodrigo de Andrade Natal,
Victor Cabello,
Livia Cons,
Marina Pavanello,
Luíz Carlos Zeferino,
Max S. Mano,
Rudinei Diogo Marques Linck,
Leticia Souza Batista,
Estela Pantarotto Pedro,
Bruno Henrique de Paula,
Gustavo Zuca-Matthes,
Emily L. Podany,
Shalini Makawita,
Kelsey A. Stewart,
Spiridon Tsavachidis,
Rull Tamimi,
Melissa L. Bondy,
Logan C. DeBord,
Matthew J. Ellis,
José Bines,
César Cabello
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac050
Subject(s) - medicine , breast cancer , cancer , oncology , cancer treatment , healthcare system , gynecology , health care , economic growth , economics
Background Breast cancer outcomes among patients who use safety-net hospitals in the highly populated Harris County, Texas and Southeast Brazil are poor. It is unknown whether treatment delay contributes to these outcomes. Methods We conducted a retrospective cohort analysis of patients with non-metastatic breast cancer diagnosed between January 1, 2009 and December 31, 2011 at Harris Health Texas and Unicamp’s Women’s Hospital, Barretos Hospital, and Brazilian National Institute of Cancer, Brazil. We used Cox proportional hazards regression to evaluate association of time to treatment and risk of recurrence (ROR) or death. Results One thousand one hundred ninety-one patients were included. Women in Brazil were more frequently diagnosed with stage III disease (32.3% vs. 21.1% Texas; P = .002). Majority of patients in both populations had symptom-detected disease (63% in Brazil vs. 59% in Texas). Recurrence within 5 years from diagnosis was similar 21% versus 23%. Median time from diagnosis to first treatment defined as either systemic therapy (chemotherapy or endocrine therapy) or surgery, were comparable, 9.9 weeks versus 9.4 weeks. Treatment delay was not associated with increased ROR or death. Higher stage at diagnosis was associated with both increased ROR and death. Conclusion Time from symptoms to treatment was considerably long in both populations. Treatment delay did not affect outcomes. Impact Access to timely screening and diagnosis of breast cancer are priorities in these populations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom